Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Drugs In Development, 2022, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.
Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 4, 4 and 7 respectively.
Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Presbyopia - Overview
Presbyopia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Presbyopia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Presbyopia - Companies Involved in Therapeutics Development
AbbVie Inc
Cellix Bio Pvt Ltd
Eyenovia Inc
Glaukos Corp
KSbitugen Co Ltd
Kubota Vision Inc
Lenz Therapeutics LLC
Novartis AG
Ocuphire Pharma Inc
Orasis Pharmaceuticals Ltd
Plex Pharmaceuticals Inc
Reven Holdings Inc
Santen Pharmaceutical Co Ltd
Seinda Pharmaceutical Guangzhou Corp
Theratocular Biotek Co Ltd
Visus Therapeutics Inc
Vyluma Inc
Zhejiang Raytone Biotechnology Co Ltd
Presbyopia - Drug Profiles
(aceclidine + brimonidine) - Drug Profile
Product Description
Mechanism Of Action
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
(brimonidine tartrate + carbachol) - Drug Profile
Product Description
Mechanism Of Action
(diclofenac sodium + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
(phentolamine mesylate + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
aceclidine - Drug Profile
Product Description
Mechanism Of Action
AGN-241622 - Drug Profile
Product Description
Mechanism Of Action
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
CLXOPH-561 - Drug Profile
Product Description
Mechanism Of Action
GLK-302 - Drug Profile
Product Description
Mechanism Of Action
Kinase Derivatives - Drug Profile
Product Description
Mechanism Of Action
KSB-10201 - Drug Profile
Product Description
Mechanism Of Action
KT-101 - Drug Profile
Product Description
Mechanism Of Action
NVK-029 - Drug Profile
Product Description
Mechanism Of Action
phentolamine mesylate - Drug Profile
Product Description
Mechanism Of Action
pilocarpine - Drug Profile
Product Description
Mechanism Of Action
RPEC-1004A - Drug Profile
Product Description
Mechanism Of Action
RTP-003A - Drug Profile
Product Description
Mechanism Of Action
RTP-003B - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
Small-Molecule Therapeutics - Drug Profile
Product Description
Mechanism Of Action
SY-301 - Drug Profile
Product Description
Mechanism Of Action
TOO-1005 - Drug Profile
Product Description
Mechanism Of Action
ursodiol - Drug Profile
Product Description
Mechanism Of Action
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
Presbyopia - Dormant Projects
Presbyopia - Product Development Milestones
Featured News & Press Releases
Nov 02, 2022: Ocuphire announces peer-reviewed publication in BMC Ophthalmology for Nyxol and strategic partnership with American Society of Ophthalmic Administrators (ASOA)
Oct 28, 2022: Ocuphire announces poster presentations on Nyxol at the American Academy of Optometry Annual Meeting
Oct 20, 2022: Eyenovia announces positive results from VISION-2 phase 3 study of MicroLine as a potential on-demand treatment for presbyopia
Oct 03, 2022: Ocuphire announces upcoming presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Jul 06, 2022: Eyenovia strategic partner Arctic Vision enrolls first patient in phase III clinical trial of ARVN003 (MicroLine) for Presbyopia in China
Jul 05, 2022: Arctic Vision enrols first subject in Phase III presbyopia trial
Apr 27, 2022: Visus Therapeutics announces new scientific data to be presented during the 2022 ARVO Annual Meeting
Apr 26, 2022: Ocuphire announces upcoming clinical presentation on Nyxol at ARVO 2022 Medical Meeting and MODLive! 2022
Apr 23, 2022: Orasis Pharmaceuticals announces phase 2b trial efficacy and safety results of novel presbyopia eye drop candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Apr 21, 2022: Orasis Pharmaceuticals announces positive phase 3 topline results of Novel Eye Drop Candidate, CSF-1, for the treatment of presbyopia
Apr 12, 2022: Orasis Pharmaceuticals to present new data on novel presbyopia candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Mar 22, 2022: Visus Therapeutics initiates phase 3 pivotal trials of BRIMOCHOL PF for the treatment of presbyopia
Mar 15, 2022: Orasis Pharmaceuticals concludes phase 3 clinical trials for presbyopia candidate
Feb 08, 2022: Ocuphire completes enrollment in MIRA-3 Pivotal phase 3 clinical trial for Nyxol in RM and announces upcoming medical conference presentation
Jan 11, 2022: Glaukos announces first patient enrolled in phase 2 clinical trial for presbyopia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Presbyopia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Presbyopia - Pipeline by AbbVie Inc, 2022
Presbyopia - Pipeline by Cellix Bio Pvt Ltd, 2022
Presbyopia - Pipeline by Eyenovia Inc, 2022
Presbyopia - Pipeline by Glaukos Corp, 2022
Presbyopia - Pipeline by KSbitugen Co Ltd, 2022
Presbyopia - Pipeline by Kubota Vision Inc, 2022
Presbyopia - Pipeline by Lenz Therapeutics LLC, 2022
Presbyopia - Pipeline by Novartis AG, 2022
Presbyopia - Pipeline by Ocuphire Pharma Inc, 2022
Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, 2022
Presbyopia - Pipeline by Plex Pharmaceuticals Inc, 2022
Presbyopia - Pipeline by Reven Holdings Inc, 2022
Presbyopia - Pipeline by Santen Pharmaceutical Co Ltd, 2022
Presbyopia - Pipeline by Seinda Pharmaceutical Guangzhou Corp, 2022
Presbyopia - Pipeline by Theratocular Biotek Co Ltd, 2022
Presbyopia - Pipeline by Visus Therapeutics Inc, 2022
Presbyopia - Pipeline by Vyluma Inc, 2022
Presbyopia - Pipeline by Zhejiang Raytone Biotechnology Co Ltd, 2022
Presbyopia - Dormant Projects, 2022
List of Figures
Number of Products under Development for Presbyopia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
